During our previously reported studies (1) on the absorption of aureomycin in humans after oral and intramuscular administration, we found that aureomycin was sometimes present in the cerebrospinal fluid. We have extended these studies in order to determine the conditions under which aureomycin will be detectable. The present paper includes the cerebrospinal fluid findings in 26 subjects with no inflammation of the central nervous system and in one patient with meningitis and two with encephalitis together with a small number of tests for aureomycin concentration in urine and in pleural and ascitic fluids.
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METHOD
Cerebrospinal fluid specimens were obtained simultaneously with specimens of serum on two patients after a single dose of 2 gm. by mouth, on four after a single 1 gm. dose, and on 18 patients who were under treatment with aureomycin 2 in doses of 250 to 500 mg. every three hours by mouth. Five subjects were given a single intravenous dose of 500 mg. of aureomycin and a single specimen of blood and spinal fluid was taken three or four hours later. One patient with a pleural effusion was given oral aureomycin and simultaneous blood and pleural fluid specimens were obtained. The same procedure was followed in the case of a patient with cirrhosis and ascites.
Aureomycin concentrations were determined by a modification of Dornbush's (2) method, as previously described by us (1) .
RESULTS
Distribution into the Cerebrospinal Fluid. As shown in Figure 1, 
DISCUSSION
It is apparent that after the first 24 hours of therapy with the doses of aureomycin in common use, detectable levels of the antibiotic are consistently present in the cerebrospinal fluid. Larger doses, producing higher serum concentrations, should result in higher cerebrospinal fluid levels. In some instances the antibiotic is present three hours after an intravenous injection of 500 mg. It is likely that higher intravenous doses might assure the presence of the antibiotic in the spinal fluid in all cases within a few hours. It is of interest that the one patient with pneumococcic meningitis whom we treated with oral doses of aureomycin recovered. The concentration of aureomycin in his cerebrospinal fluid was not detectable 12 hours after the start of therapy, but was 0.06 to 0.13 MAg. thereafter. This patient received two doses of sulfonamides before aureomycin was started. These may have prevented the progression of the meningitis before aureomycin was available at the site of the infection, although we doubt that they could have been responsible for the patient's recovery. In this connection, it is of interest that we have found the sensitivity of 26 strains of pneumococci to range between 0.01 and 0.16 ug. of aureomycin. Seventeen of the strains were sensitive to 0.02 jug. or less. Our preliminary studies show that aureomycin can be transmitted into the pleural and ascitic fluids when it is administered systemically. Whether this is true in all cases and whether the concentrations are sufficient for therapeutic effects are problems which await further study. The large volumes of urine obtained in some cases, and our observations on a number of patients under treatment with aureomycin, lead us to believe that aureomycin has a diuretic effect. The amount excreted is closely related to the serum concentration, the ratio of serum concentration to urine concentration being in the neighborhood of 1: 100. This makes it likely that aureomycin is excreted as a glomerular filtrate. From our previous studies (1) 2. Aureomycin has been found in the pleural and ascitic fluids of two patients after oral administration.
3. Urine studies on eight patients showed an aureomycin concentration of 12.5 to 100 ttg./cc.
during the first hour after oral or intravenous administration, depending upon the height of the serum concentration and the volume of urine excreted. The ratio of the aureomycin concentrations of serum to urine was approximately 1: 100.
